<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    electroCore, Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About electroCore, Inc.

    electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s current indications are for the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $426,000,000
    • SIC CODE
      3845
    • NIN CODE
      ####
    • LEADERSHIP
      Francis R. Amato
    • FOUNDED
      2005
    • EMPLOYEES
      51-100
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    REGENXBIO Inc.

    REGENXBIO Inc.

    REGENXBIO is a leading biotechnology company focused on the development, commercia...

    REGENXBIO is a leading biotechnology company fo...

    Filing Type:    PU
    Axovant Gene Therapies Ltd.

    Axovant Gene Therapies Ltd.

    Axovant is accelerating the development of innovative gene therapy products that a...

    Axovant is accelerating the development of inno...

    Filing Type:    PU
    Nemucore Medical Innovations, Inc.

    Nemucore Medical Innovations, Inc.

    Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...

    Nemucore Medical Innovations is here to bring y...

    Amount Raised:    $92,318.00
    Fundraising Status:    EC
    Filing Type:    CF
    DBV Technologies S.A.

    DBV Technologies S.A.

    DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...

    DBV Technologies is developing ViaskinÂŽ, an in...

    Filing Type:    PU
    Astellas Pharma, Inc.

    Astellas Pharma, Inc.

    Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...

    Astellas Pharma Inc. is a pharmaceutical compan...

    Filing Type:    PU
    Anika Therapeutics Inc.

    Anika Therapeutics Inc.

    Headquartered in Bedford, Massachusetts, Anika Therapeutics, Inc. develops, manufa...

    Headquartered in Bedford, Massachusetts, Anika ...

    Filing Type:    PU
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    Collegium Pharmaceutical, Inc.

    Collegium Pharmaceutical, Inc.

    Collegium Pharmaceutical is a specialty pharmaceutical company committed to being ...

    Collegium Pharmaceutical is a specialty pharmac...

    Filing Type:    PU
    Mesoblast Limited

    Mesoblast Limited

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...

    Filing Type:    PU
    Evelo Biosciences, Inc.

    Evelo Biosciences, Inc.

    Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...

    Evelo Biosciences, Inc. is a clinical stage bio...

    Filing Type:    PU
    Chiasma, Inc.

    Chiasma, Inc.

    Chiasma is focused on improving the lives of patients who face challenges associat...

    Chiasma is focused on improving the lives of pa...

    Filing Type:    PU
    BioDelivery Sciences International, Inc.

    BioDelivery Sciences International, Inc.

    BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...

    BioDelivery Sciences International, Inc. (NASDA...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.